Outcomes of Patients With International Germ Cell Cancer Collaborative Group Good Prognosis Metastatic Seminoma Undergoing De‐Escalation Chemotherapy: A Single‐Center Retrospective Study
International Journal of Urology · 2025
DOI: 10.1111/iju.70118 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Takahiro Kirisawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Retroperitoneal Surgery, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Seminoma, Testicular Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Induction Chemotherapy. Die Arbeit nennt 19 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To compare the survival outcomes of de‐escalation chemotherapy with those of standard first‐line chemotherapy in patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis metastatic seminoma.
Methods
The cohort of this retrospective, observational, single‐center study comprised 35 patients with clinical Stage I (CSI)‐relapsed or de novo IGCCCG good prognosis metastatic seminoma who had undergone induction chemotherapy at our institution between 2007 and 2021. Patients were allocated to standard or de‐escalation therapy groups according to average relative dose intensity (ARDI) of induction chemotherapy: ARDI ≥ 90 and ARDI < 90. Overall and recurrence‐free survival were compared between these groups using Kaplan–Meier curves and the log‐rank test.
Results
The de‐escalation therapy regimen included three cycles of etoposide and cisplatin (66.7%). Overall and relapse‐free survival of patients undergoing de‐escalation therapy and that of patients undergoing standard therapy were comparable. In addition, rates of adverse events, including hearing impairment and peripheral neuropathy induced by cisplatin‐containing chemotherapy, were slightly, but not significantly, lower in the de‐escalation therapy group than in the standard therapy group.
Conclusions
Our findings provide a preliminary experimental basis for the development of de‐escalation therapy for IGCCCG good prognosis metastatic seminoma. If sufficient tumor regression is achieved, de‐escalation therapy incorporating three cycles of etoposide/cisplatin therapy could be considered acceptable for patients with relatively low metastatic tumor burdens, such as those with Stage II CSI‐relapsed seminoma. Further studies to validate the efficacy of de‐escalation therapy are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Retroperitoneal Surgery, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Takahiro Kirisawa, Yasuo Shinoda
Zitieren
APA
Kirisawa, T., Hagimoto, H., Okuno, T., Matsuda, A., Maejima, A., Shinoda, Y., Nakamura, E., Komiyama, M., Fujimoto, H., & Matsui, Y. (2025). Outcomes of Patients With International Germ Cell Cancer Collaborative Group Good Prognosis Metastatic Seminoma Undergoing De‐Escalation Chemotherapy: A Single‐Center Retrospective Study. International Journal of Urology. https://doi.org/10.1111/iju.70118
Vancouver
Kirisawa T, Hagimoto H, Okuno T, Matsuda A, Maejima A, Shinoda Y, et al. Outcomes of Patients With International Germ Cell Cancer Collaborative Group Good Prognosis Metastatic Seminoma Undergoing De‐Escalation Chemotherapy: A Single‐Center Retrospective Study. International Journal of Urology. 2025. doi:10.1111/iju.70118
BibTeX
@article{Kirisawa2025,
author = {Kirisawa, Takahiro and Hagimoto, Hiroki and Okuno, Tomoya and Matsuda, Ayumu and Maejima, Aiko and Shinoda, Yasuo and Nakamura, Eijiro and Komiyama, Motokiyo and Fujimoto, Hiroyuki and Matsui, Yoshiyuki},
title = {Outcomes of Patients With International Germ Cell Cancer Collaborative Group Good Prognosis Metastatic Seminoma Undergoing De‐Escalation Chemotherapy: A Single‐Center Retrospective Study},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70118}
}
EUVIMED